» Articles » PMID: 24498197

Enlarged Memory T-cell Pool and Enhanced Th1-type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy

Overview
Journal PLoS One
Date 2014 Feb 6
PMID 24498197
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

A small proportion of chronic myeloid leukemia patients treated with interferon-α (IFN-α) monotherapy are able to discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that these patients have increased amount of NK-cells and a distinct blood cytokine profile. We now aimed to study the function of NK- and T-cells in order to understand the role of the immune system in maintaining the treatment response after IFN-α discontinuation. The study included 13 patients: 5 patients were still treated with IFN-α monotherapy (IFN-ON, median treatment time 163 months) and 8 had stopped the treatment successfully (IFN-OFF, median time without therapy 42 months). Detailed immunophenotype and cytokine production of NK- and T-cells was analyzed with flow cytometry. In addition, the cytotoxicity of NK-cells was studied using K562 as target cells and both the degranulation and direct killing was measured. Compared to healthy controls, IFN-OFF patients had increased proportion of CD4(+) effector memory (CCR7(-)CD45RA(-); median 23% vs. healthy 16%, p = 0.009) and CD8(+) central memory T-cells (CCR7(+)CD45RA(-); median 26% vs. healthy 14%, p = 0.004). Further, upon stimulation the IFN-γ/TNF-α cytokine secretion by CD4(+) T-cells was significantly enhanced in IFN-OFF patients (median 13.7% vs. healthy 7.8%, p = 0.01), and CD4+ effector and central memory cells were the main cytokine producers. No similar increase was observed in IFN-ON group (6.5%). In addition, the proportion of NK-cells was significantly increased in IFN-OFF patients (median IFN-OFF 24%, healthy 13%, p = 0.04), but their direct killing of K562 cells was impaired. The cytotoxicity of NK-cells was also diminished in IFN-ON patients. To conclude, in addition to elevated NK-cell count, IFN-OFF patients have increased amount of memory T-cells, which are able to induce strong cytokine response upon stimulation. This activity may contribute to the maintenance of prolonged remission after successful IFN-α discontinuation.

Citing Articles

Systematic review and quantitative meta-analysis of age-dependent human T-lymphocyte homeostasis.

Kulesh V, Peskov K, Helmlinger G, Bocharov G Front Immunol. 2025; 16:1475871.

PMID: 39931065 PMC: 11808020. DOI: 10.3389/fimmu.2025.1475871.


Targeting cytokine and chemokine signaling pathways for cancer therapy.

Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K Signal Transduct Target Ther. 2024; 9(1):176.

PMID: 39034318 PMC: 11275440. DOI: 10.1038/s41392-024-01868-3.


CD4 T cells in chronic myeloid leukemia present MHC class II-dependent and IFN-γ-dependent cytotoxic capacity.

Jiang Y, Yao J, Yao Z, Huang Y, Li Z, Fan Z Med Oncol. 2023; 40(9):253.

PMID: 37498412 DOI: 10.1007/s12032-023-02123-5.


Anti-CD19 chimeric antigen receptor T-cell followed by interferon-α therapy induces durable complete remission in donor cell-derived acute lymphoblastic leukemia: A case report.

Ni J, Zhou J, Long Z, Chen X, Chen X, Hong J Front Oncol. 2022; 12:1021786.

PMID: 36505803 PMC: 9731404. DOI: 10.3389/fonc.2022.1021786.


IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.

Huuhtanen J, Ilander M, Yadav B, Dufva O, Lahteenmaki H, Kasanen T J Clin Invest. 2022; 132(17).

PMID: 36047494 PMC: 9433106. DOI: 10.1172/JCI152585.


References
1.
Thielen N, van der Holt B, Cornelissen J, Verhoef G, Gussinklo T, Biemond B . Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013; 49(15):3242-6. DOI: 10.1016/j.ejca.2013.06.018. View

2.
Wu S, Zheng C, Xu J . [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α]. Zhonghua Xue Ye Xue Za Zhi. 2012; 33(4):311-5. View

3.
Juelke K, Killig M, Luetke-Eversloh M, Parente E, Gruen J, Morandi B . CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood. 2010; 116(8):1299-307. DOI: 10.1182/blood-2009-11-253286. View

4.
Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet. 2007; 370(9584):342-50. DOI: 10.1016/S0140-6736(07)61165-9. View

5.
Campbell K, Hasegawa J . Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013; 132(3):536-544. PMC: 3775709. DOI: 10.1016/j.jaci.2013.07.006. View